Goldman Sachs Group Inc Ab Cellera Biologics Inc. Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 86,483 shares of ABCL stock, worth $204,964. This represents 0.0% of its overall portfolio holdings.

Number of Shares
86,483
Previous 86,483 -0.0%
Holding current value
$204,964
Previous $192,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
SELL
$2.2 - $3.53 $469,326 - $753,054
-213,330 Reduced 71.15%
86,483 $192,000
Q4 2024

Feb 11, 2025
BUY
$2.48 - $3.15 $233,382 - $296,433
94,106 Added 45.75%
299,813 $878,000
Q3 2024

Nov 14, 2024
BUY
$2.39 - $3.49 $262,754 - $383,687
109,939 Added 114.8%
205,707 $532,000
Q2 2024

Aug 13, 2024
SELL
$2.73 - $4.73 $302,099 - $523,417
-110,659 Reduced 53.61%
95,768 $283,000
Q1 2024

May 15, 2024
SELL
$4.29 - $5.97 $1.69 Million - $2.36 Million
-394,814 Reduced 65.67%
206,427 $935,000
Q4 2023

Feb 13, 2024
BUY
$3.91 - $5.93 $1.34 Million - $2.03 Million
341,945 Added 131.87%
601,241 $3.43 Million
Q3 2023

May 14, 2024
SELL
$4.6 - $7.95 $1.57 Million - $2.72 Million
-341,945 Reduced 56.87%
259,296 $1.19 Million
Q3 2023

Nov 14, 2023
SELL
$4.6 - $7.95 $740,512 - $1.28 Million
-160,981 Reduced 38.3%
259,296 $1.19 Million
Q2 2023

May 14, 2024
BUY
$5.66 - $7.59 $390,149 - $523,186
68,931 Added 19.62%
420,277 $2.71 Million
Q2 2023

Aug 14, 2023
BUY
$5.66 - $7.59 $390,149 - $523,186
68,931 Added 19.62%
420,277 $2.71 Million
Q1 2023

May 14, 2024
SELL
$7.31 - $11.18 $829,904 - $1.27 Million
-113,530 Reduced 24.42%
351,346 $2.65 Million
Q1 2023

May 11, 2023
SELL
$7.31 - $11.18 $829,904 - $1.27 Million
-113,530 Reduced 24.42%
351,346 $2.65 Million
Q4 2022

May 14, 2024
BUY
$9.48 - $14.52 $603,487 - $924,328
63,659 Added 15.87%
464,876 $4.71 Million
Q4 2022

Feb 13, 2023
BUY
$9.48 - $14.52 $603,487 - $924,328
63,659 Added 15.87%
464,876 $4.71 Million
Q3 2022

May 14, 2024
BUY
$9.2 - $13.68 $1.53 Million - $2.28 Million
166,730 Added 71.1%
401,217 $3.97 Million
Q3 2022

Nov 10, 2022
BUY
$9.2 - $13.68 $1.53 Million - $2.28 Million
166,730 Added 71.1%
401,217 $3.97 Million
Q2 2022

May 14, 2024
SELL
$5.72 - $10.65 $2.1 Million - $3.91 Million
-366,754 Reduced 61.0%
234,487 $2.5 Million
Q2 2022

Aug 15, 2022
BUY
$5.72 - $10.65 $696,478 - $1.3 Million
121,762 Added 108.02%
234,487 $2.5 Million
Q1 2022

May 16, 2022
SELL
$7.46 - $14.14 $169,521 - $321,317
-22,724 Reduced 16.78%
112,725 $1.1 Million
Q4 2021

Feb 14, 2022
BUY
$12.99 - $17.73 $1.52 Million - $2.07 Million
116,704 Added 622.59%
135,449 $1.94 Million
Q3 2021

Nov 10, 2021
BUY
$14.85 - $21.34 $278,363 - $400,018
18,745 New
18,745 $376,000

Others Institutions Holding ABCL

# of Institutions
150
Shares Held
132M
Call Options Held
156K
Put Options Held
346K
View Full List

About AbCellera Biologics Inc.

ABCL Quotes by TradingView
  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $676M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email